ABLEPHARON-MACROSTOMIA SYNDROME
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Age was found to be significantly associated with the EPAS1 SNP in the CMS patients while heart rate (HR) and oxygen saturation level of hemoglobin (SaO(2)) were found to be significantly associated with the EGLN1 (rs480902) SNP in the Han patients with AMS.
|
22595196 |
2012 |
ABLEPHARON-MACROSTOMIA SYNDROME
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The rs4953348 polymorphism of EPAS1 gene had a significant correlation with the SaO2 level and AMS, and a significant difference in the AG and GG genotype distribution between the AMS and non-AMS groups.
|
27982053 |
2016 |
Acute Erythroblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ptpmt1 induced by HIF-2α regulates the proliferation and glucose metabolism in erythroleukemia cells.
|
26898802 |
2016 |
Acute kidney injury
|
0.200 |
Therapeutic
|
disease |
RGD |
Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure.
|
16762988 |
2006 |
Acute monocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance.
|
26642852 |
2015 |
Acute mountain sickness
|
0.010 |
Biomarker
|
disease |
BEFREE |
Three SNPs within EPAS1 and EGLN1 were evaluated in Han and Tibetan patients with acute mountain sickness (AMS) and chronic mountain sickness (CMS).
|
22595196 |
2012 |
Acute posthaemorrhagic anaemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Compared to blood loss, anemia in young CKD rats is associated with inappropriate responses in the HIF-EPO-EPO-R axis: kidney HIF2α and renal EPO are not increased, BM and bone EPOR levels, as well as bone pSTAT5 response to EPO are reduced.
|
29738538 |
2018 |
Acute respiratory distress
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hypoxia-inducible-factor-2α (HIF-2α) and HIF-2 degrading prolyl-hydroxylases (PHD) are key regulators of adaptive hypoxic responses i.e., in acute respiratory distress syndrome (ARDS).
|
28613249 |
2017 |
Adenocarcinoma
|
0.060 |
Biomarker
|
group |
BEFREE |
The PAI-1 gene as a direct target of endothelial PAS domain protein-1 in adenocarcinoma A549 cells.
|
15039136 |
2004 |
Adenocarcinoma
|
0.060 |
Biomarker
|
group |
BEFREE |
Poorer outcome in stromal HIF-2 alpha- and CA9-positive colorectal adenocarcinomas is associated with wild-type TP53 but not with BNIP3 promoter hypermethylation or apoptosis.
|
18728663 |
2008 |
Adenocarcinoma
|
0.060 |
AlteredExpression
|
group |
LHGDN |
Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.
|
12209691 |
2002 |
Adenocarcinoma
|
0.060 |
AlteredExpression
|
group |
LHGDN |
Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
|
17437013 |
2007 |
Adenocarcinoma
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The high HIF-2α expression was associated with histology (squamous cell carcinoma vs. adenocarcinomas) in these patients ( p = 0.001).
|
28653893 |
2017 |
Adenocarcinoma
|
0.060 |
AlteredExpression
|
group |
LHGDN |
Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas.
|
17452775 |
2007 |
Adenocarcinoma of lung (disorder)
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
We showed that EPAS1, but not HIF-1alpha, is abundantly expressed in human lung adenocarcinoma A549 cells.
|
11751212 |
2002 |
Adenocarcinoma of lung (disorder)
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin.
|
29469087 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.070 |
Biomarker
|
disease |
BEFREE |
Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma.
|
29859855 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
In vivo PDK4 expression was elevated in a Cisplatin-resistant population of lung adenocarcinoma cells, PDK4-dependent Cisplatin-resistance promotes tumor growth of lung adenocarcinoma in vivo and in vitro, clinically PDK4 expression was associated with poor prognosis in lung adenocarcinoma patients, mechanically PDK4 promoted cell growth and Cisplatin-resistance of lung adenocarcinoma via transcriptional regulation of endothelial PAS domain-containing protein 1 (EPAS1).
|
30501603 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Moreover, HIF-2α expression was linked to a good survival benefit in some cancers (B-cell lymphoma and lung adenocarcinoma: OS, multiple myeloma: DSS, breast cancer: distant metastasis-free survival, liposarcoma: distant recurrence-free survival) (all HRs < 1, Ps < 0.05).
|
30021192 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
The EPAS1 rs4953354 may be a potentially susceptible marker for development of lung adenocarcinoma, especially in female never-smokers.
|
25436804 |
2014 |
Adenocarcinoma of lung (disorder)
|
0.070 |
Biomarker
|
disease |
BEFREE |
Mega-analysis revealed that three LA-associated genes, such as solute carrier family 2 member 1 (SLC2A1), endothelial PAS domain protein 1 (EPAS1) and cyclin-dependent kinase 4 (CDK4), were significantly associated with LSCC (P<1.60×10<sup>-8</sup>), with multiple potential pathways identified by functional pathway analysis, which were further validated by co-expression analysis.
|
31516564 |
2019 |
Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
|
28667082 |
2017 |
Adrenal Gland Pheochromocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.
|
16954163 |
2006 |
Adrenal Gland Pheochromocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The HIF2α mutation-induced polycythemia with PCC/PGL is a rare syndrome with no treatment for cure.
|
28116635 |
2017 |
Adrenal Gland Pheochromocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This case represents the first association of a somatic HIF2A gain-of-function mutation with PHEO and congenital polycythemia, and it alerts physicians to perform proper genetic screening in patients presenting with multiple norepinephrine-producing PHEOs and polycythemia.
|
23539726 |
2013 |